Format

Send to

Choose Destination
Leuk Res. 2014 Jan;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011. Epub 2013 Sep 23.

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.

Author information

1
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. Electronic address: simona.soverini@tin.it.
2
Department of Molecular Pathology, SA Pathology, Centre for Cancer Biology, Adelaide, Australia; School of Medicine, University of Adelaide, Adelaide, Australia; School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia.
3
Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
4
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
5
Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
6
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
7
III Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany.
8
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
9
Department of Hematology/Oncology, University of California, San Francisco, CA, USA.

Abstract

Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations.

KEYWORDS:

BCR-ABL1; Chronic myeloid leukemia; Kinase domain; Mutations; Philadelphia chromosome; Resistance; Tyrosine kinase inhibitors

PMID:
24131888
DOI:
10.1016/j.leukres.2013.09.011
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center